# TELL Abbott TO STOP CASHING IN ON SALVAGE THERAPY!

Did you know:

- That Abbott has recently increased the cost of its protease inhibitor Norvir (ritonavir) by greater than 400%?
- That Norvir is the only drug recommended to help boost the levels (and effectiveness) of other protease inhibitors (PIs)?
- That such a price increase will double the cost of some PI therapies?

Abbott claims the higher costs are necessary and that Norvir will still cost less than some other protease inhibitors (PIs). They also say that boosting other drugs with small doses of Norvir has resulted in lower sales of Norvir. The real story is that they are worried that their other drug, Kaletra (also a boosted PI), won't sell as well because of the approval of new PIs. But these new PIs are stronger when boosted, especially in "salvage" patients with few drug options left. **So, greedy Abbott is cashing in at the expense of salvage patients.**

Abbott should be thankful that Norvir is being used so widely as a boosting agent. Full-strength Norvir has harsh side effects and would not be used AT ALL if not for its boosting properties.

What to do:

- Contact Abbott CEO Miles White (847-937-6100) and tell him to stop contributing to the AIDS crisis in this country. This is not fair to people with AIDS.
- Contact the AIDS Treatment Activists Coalition for more information or to get involved: **www.atac-usa.org**.

AIDS treatment ATAC activists coalition